Click here to check the ultimate guide to learn how to leverage your PC and internet to make money online.
The Washington Independent
The Washington Independent

NCI offers explanation for changes to its medical marijuana database entry

The National Cancer Institute (NCI) has now published online an explanation for changes made to its treatment database entry on cannabis that The American

Katharine Tate
News
Last updated: Jul 31, 2020 | Mar 31, 2011

Image has not been found. URL: http://images.americanindependent.com/marijuanathumb.jpgThe National Cancer Institute (NCI) has now published online an explanation for changes made to its treatment database entry on cannabis that The American Independent previously reported on.

The explanation states that the information available in NCI’s so-called “PDQ” (Physician Data Query) summaries are not treatment recommendations and are not representative of any federal policy.

The full text of the explanation:

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

In writing Cancer Information Summaries, PDQ Editorial Boards review current evidence. They do not make recommendations. Their work is editorially independent of the National Cancer Institute (NCI). The summary on Cannabis and cannabinoids does not represent a policy statement of NCI or NIH. The summary statement represents an independent review of the literature; that review is not influenced by NCI or any other federal agency.

In light of the attention garnered by the PDQ summary statement on Cannabis and cannabinoids, reviewers for the summary on the PDQ Complementary and Alternative Medicine (CAM) Editorial Board reexamined the recently posted statement and decided to change the wording, in order to clarify the meaning that the Board originally intended to convey and to correct several possible misinterpretations. The changes made and the rationales for them are:

  • In the General Information section, the wording was revised to make clearer that Cannabis is not approved by the FDA for any medical use.
  • In the General Information section, a sentence was replaced to add clarification. The CAM Board lead reviewers realized that the previous wording could have been misinterpreted as being a recommendation for prescribing Cannabis, which was not the intent of the Board. In addition, the current evidence for the antitumor properties of Cannabis is discussed only in the context of laboratory studies and not in research involving human subjects. It is discussed only in the summary section titled Laboratory/Animal/Preclinical Studies.
  • In the last sentence of the Adverse Effects section under Cannabinoids, the words “severe or abrupt” were added for clarification.

Readers of the PDQ Cannabis and Cannabinoids summary should note that no changes were made to the Overall Level of Evidence for Cannabis and Cannabinoids section. This section provides levels of evidence related to the use of cannabinoids and Cannabis.

As part of the regular process for all PDQ Editorial Boards, the CAM Editorial Board plans to further review the literature and discuss other potential revisions to the summary.

As the explanation mentions, there is now a further revision to the summary of cannabis. It states:

The U.S. Food and Drug Administration (FDA) has not approved the use of Cannabis as a treatment for any medical condition. To conduct clinical drug research in the United States, researchers must file an Investigational New Drug (IND) application with the FDA.

An IND application is the first step in initiating clinical trials that can lead to FDA approval of a drug. While the new sentence is certainly by no means intended to be an official endorsement of seeking FDA approval of medical marijuana, it’s interesting to note that the concept of applying for IND approval is even acknowledged. The FDA stopped discontinued IND trials of marijuana in 1991 because of the glut of people seeking legal, FDA-approved access to the drug.

Katharine Tate | I’m a native of Massachusetts, where I earned bachelor's degrees in Health: Science, Society, and Policy and Sculpture from Brandeis University. I enjoy assisting and inspiring women in all aspects of their lives, and I consider myself a partner in their OB an GYN treatment. I particularly enjoy forming relationships with young women and assisting them in determining their healthcare needs and goals. I love to travel, create metal and fiber art, cook, and spend time outside. Also, I’m fluent in both German and American Sign Language.

Related

MA-Sen: A Text Message From Scott Brown

BOSTON -- Having signed up for Scott Brown’s text message service for election day, I just got this text: Are you about to have lunch? It’s a great time to

MA-Sen: 150 Conservative Bloggers Fan Out, Looking for Scandals

BOSTON -- The mysterious Election Journal blog, which first released the infamous 2008 video of two bumbling New Black Panther Party members waving nightsticks

MA-Sen: Brown Wins

BOSTON -- At 9:20, the first rumors of Scott Brown’s victory in the Massachusetts Senate race started to work around the room. A moment later, Doug Flutie

MA-Sen: 66 to 19

BOSTON -- That, via Alex Isenstadt and Josh Kraushaar, is the number that defined the Massachusetts Senate race more than anything else. From the primary

MA-Sen: Out-of-Staters for Brown

BOSTON -- A surprising discovery at yesterday’s People’s Rally in Worcester was just how many people had traveled into the state to assist, in whatever way,

MA-Sen: Loyal Democrats Grouse About Coakley

BOSTON -- A little while after noon, a steady crowd of Democratic voters streamed into the Cathedral High School Gymnasium to cast votes for their party’s

MA-Sen: Republicans Celebrate Coakley’s Gaffes in Worcester

WORCESTER, Mass. - By the way, said Curt Schilling. One more thing. I am not a Yankees fan. The overflowing crowd at Worcester’s Mechanics Hall on

Menendez, Lautenberg to Continue BP-Lockerbie Investigation

Sens. Robert Menendez and Frank Lautenberg, both New Jersey Democrats, will continue to seek details about BP’s alleged involvement in the release last year of

Net Investors Bullish on Palin’s Prospects for Staying on Ticket

Just for fun, the Internet prediction Website Intrade has opened a contract on whether Alaska Gov. Sarah Palin will be withdrawn as McCain’s running mate.

No Experience Necessary

Gov. Sarah Palin’s a middle-class hockey mom, but does that really qualify her to be vice president?

© Copyright 2022 The Washington Independent All Rights Reserved

Terms & Privacy | twi.news@washingtonindependent.com

Click here to check the ultimate guide to learn how to leverage your PC and internet to make money online.